Tanezumab

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Name
Tanezumab
Accession Number
DB12335
Type
Biotech
Groups
Investigational
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Description

Tanezumab has been investigated for the treatment of Osteoarthritis, Knee and Neuralgia, Postherpetic.

Protein chemical formula
Not Available
Protein average weight
Not Available
Sequences
Not Available
Synonyms
Not Available
External IDs
RN624
Categories
UNII
EQL0E9GCX1
CAS number
880266-57-9

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
AbciximabThe risk or severity of adverse effects can be increased when Abciximab is combined with Tanezumab.
AbituzumabThe risk or severity of adverse effects can be increased when Tanezumab is combined with Abituzumab.
AbrilumabThe risk or severity of adverse effects can be increased when Tanezumab is combined with Abrilumab.
AdalimumabThe risk or severity of adverse effects can be increased when Adalimumab is combined with Tanezumab.
AdecatumumabThe risk or severity of adverse effects can be increased when Adecatumumab is combined with Tanezumab.
AducanumabThe risk or severity of adverse effects can be increased when Aducanumab is combined with Tanezumab.
AfelimomabThe risk or severity of adverse effects can be increased when Afelimomab is combined with Tanezumab.
AlemtuzumabThe risk or severity of adverse effects can be increased when Alemtuzumab is combined with Tanezumab.
AlirocumabThe risk or severity of adverse effects can be increased when Alirocumab is combined with Tanezumab.
AmatuximabThe risk or severity of adverse effects can be increased when Tanezumab is combined with Amatuximab.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Substance
347911318
Wikipedia
Tanezumab

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedTreatmentBack Pain Lower Back Chronic / Osteoarthritis Pain / Pain Due to Interstitial Cystitis1
1CompletedTreatmentHealthy Volunteers1
1, 2CompletedTreatmentKnee Osteoarthritis (Knee OA)1
2CompletedTreatmentArthritis / OA Knee Pain / Osteoarthritis (OA)1
2CompletedTreatmentBack Pain Lower Back2
2CompletedTreatmentChronic Prostatitis With Chronic Pelvic Pain Syndrome1
2CompletedTreatmentNeoplasms Metastasis / Palliative Care1
2CompletedTreatmentOsteoarthritis (OA)1
2CompletedTreatmentPostherpetic Neuralgia1
2TerminatedNot AvailableKnee Osteoarthritis (Knee OA) / Osteoarthritis, Hip1
2TerminatedTreatmentDiabetic Peripheral Neuropathy (DPN)1
2TerminatedTreatmentEndometriosis1
2TerminatedTreatmentInterstitial Cystitis1
2TerminatedTreatmentPancreatitis, Chronic1
2, 3TerminatedTreatmentBack Pain Lower Back1
3Active Not RecruitingTreatmentBack Pain Lower Back1
3CompletedTreatmentArthritis / Osteoarthritis (OA)2
3CompletedTreatmentArthritis / Osteoarthritis (OA) / Osteoarthritis, Hip1
3CompletedTreatmentBack Pain Lower Back1
3CompletedTreatmentKnee Osteoarthritis (Knee OA) / Osteoarthritis of Hip and Knee / Osteoarthritis, Hip1
3CompletedTreatmentKnee Osteoarthritis (Knee OA) / Osteoarthritis, Hip1
3CompletedTreatmentKnee Osteoarthritis (Knee OA) / Osteoarthritis, Hip / Pain, Chronic1
3CompletedTreatmentOsteoarthritis (OA)1
3RecruitingTreatmentNeoplasms Metastasis / Orthopaedic Related Pain (Musculoskeletal Pain)1
3TerminatedTreatmentArthritis / Osteoarthritis (OA)1
3TerminatedTreatmentArthritis / Osteoarthritis (OA) / Pain NOS1
3TerminatedTreatmentOsteoarthritis (OA)6

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Taxonomy

Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available

Drug created on October 20, 2016 16:00 / Updated on June 04, 2019 07:36